ENTERA BIO IS-0000769 (5DT) - Total Assets
Based on the latest financial reports, ENTERA BIO IS-0000769 (5DT) holds total assets worth €19.48 Million EUR (≈ $22.77 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ENTERA BIO IS-0000769 - Total Assets Trend (2021–2025)
This chart illustrates how ENTERA BIO IS-0000769's total assets have evolved over time, based on quarterly financial data. Also see ENTERA BIO IS-0000769 stock valuation for the company's overall valuation and market capitalisation.
ENTERA BIO IS-0000769 - Asset Composition Analysis
Current Asset Composition (December 2025)
ENTERA BIO IS-0000769's total assets of €19.48 Million consist of 95.7% current assets and 4.4% non-current assets. Review ENTERA BIO IS-0000769 total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 44.4% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ENTERA BIO IS-0000769's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for ENTERA BIO IS-0000769 for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ENTERA BIO IS-0000769's current assets represent 95.7% of total assets in 2025, a decrease from 97.5% in 2021.
- Cash Position: Cash and equivalents constituted 44.4% of total assets in 2025, down from 95.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
ENTERA BIO IS-0000769 Competitors by Total Assets
Key competitors of ENTERA BIO IS-0000769 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
ENTERA BIO IS-0000769 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.98 | 10.47 | 6.61 |
| Quick Ratio | 8.98 | 10.47 | 6.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €16.79 Million | €17.47 Million | €6.23 Million |
ENTERA BIO IS-0000769 - Advanced Valuation Insights
This section examines the relationship between ENTERA BIO IS-0000769's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 69.82 |
| Latest Market Cap to Assets Ratio | 27.07 |
| Asset Growth Rate (YoY) | 70.3% |
| Total Assets | €15.99 Million |
| Market Capitalization | $432.85 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values ENTERA BIO IS-0000769's assets at a significant premium (27.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: ENTERA BIO IS-0000769's assets grew by 70.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ENTERA BIO IS-0000769 (2021–2025)
The table below shows the annual total assets of ENTERA BIO IS-0000769 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €15.99 Million ≈ $18.70 Million |
+70.32% |
| 2024-12-31 | €9.39 Million ≈ $10.98 Million |
-20.19% |
| 2023-12-31 | €11.77 Million ≈ $13.75 Million |
-10.38% |
| 2022-12-31 | €13.13 Million ≈ $15.35 Million |
-49.49% |
| 2021-12-31 | €25.99 Million ≈ $30.38 Million |
-- |
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more